

#### QUESTIONNAIRE - MONOCLONAL ANTIBODY DEVELOPMENT

### AGAINST AN ANTIBODY

Please fill out this form as a prerequisite for planning and specifying the major steps of the respective project.

It will also be used as the basis for quotation and further discussion of project details.

All information provided including the client information at the end of this questionnaire will be treated strictly confidential. A nondisclosure agreement can be signed upon request.

## 1. ANTIGEN INFORMATION - ANTIBODY Name: Isotype and subclass: Antibody is available as: ☐ Whole molecule ☐ F(ab')₂-Fragment ☐ scFv/Fv-Fragment ☐ Fab-Fragment Fragmentation requested? ☐ Fab-Fragment ☐ F(ab')<sub>2</sub>-Fragment □ No ☐ I am not sure yet, please provide advice. The antibody or functional parts thereof are derived from which host species: ☐ Other, please specify: ☐ Human Other modification of the antibody: ☐ Humanized ☐ Chimeric (please specify) ☐ Antibody-conjugate



## QUESTIONNAIRE - MONOCLONAL ANTIBODY DEVELOPMENT

## AGAINST AN ANTIBODY

| ANTIBODY-DRUG  | -CONJUGATE INFO                     | ORMATION (IF APPLICAE      | BLE)                    |  |  |  |
|--|-------------------------------------|----------------------------|-------------------------|--|--|--|
| Please specify the structure of the conjugate (hapten), including the linker, or specify the group that is used for conjugation to the antibody, respectively: |                                     |                            |                         |  |  |  |
| Please enter additional information on structure or characterization of the drug substance if available:   |                                     |                            |                         |  |  |  |
| Is the drug substa   | nce/ the antigen a o                | cell toxin?                |                         |  |  |  |
| □ No   | ☐ Yes, please spec                  |                            |                         |  |  |  |
| Is the antibody, or the antibody-drug-conjugate available in buffer?   |                                     |                            |                         |  |  |  |
| ☐ Yes  |                                     | □ No                       |                         |  |  |  |
| If yes, please answ  | ver the following qu                | estions:                   |                         |  |  |  |
| Availability of the pr   | rotein in buffer:                   | ] Soluble                  | ☐ Precipitated          |  |  |  |
| <b>Does the buffer contain a preservative?</b> (BioGenes does not recommend the use of preservatives)  |                                     |                            |                         |  |  |  |
| □ No   | ☐ Yes, please specify preservative: |                            |                         |  |  |  |
|  |                                     |                            |                         |  |  |  |
| 2. ANTIBODY DEVELOPMENT  |                                     |                            |                         |  |  |  |
| Should cross-reactivity testing be included?   |                                     |                            |                         |  |  |  |
| ☐ Yes  | □ No                                | ☐ I am not sure yet        |                         |  |  |  |
| If yes, please indicate kind of selection:   |                                     |                            |                         |  |  |  |
| ☐ Positive   | ☐ Negative                          | ☐ Cross-reactivity test fo | r characterization only |  |  |  |



## QUESTIONNAIRE - MONOCLONAL ANTIBODY DEVELOPMENT AGAINST AN ANTIBODY

| Are cross-reactants (commercially) available?  |                      |        |                     |  |  |
|--|----------------------|--------|---------------------|--|--|
| ☐ Yes  | □ No                 |        |                     |  |  |
| Name:  |                      |        |                     |  |  |
| Purity [%]:  |                      |        |                     |  |  |
| Molecular weight [kDa]:  |                      |        |                     |  |  |
| Cross-reactants are availa   | ible in buffer 🗌 Sol | uble [ | ☐ Precipitated      |  |  |
| Is further information about cross-reactants available (please provide)?   |                      |        |                     |  |  |
| Is the identification of monoclonal anti-idiotypic antibodies, which recognize the antibody binding site, requested? (Competitive ELISA with original antigen) |                      |        |                     |  |  |
| ☐ Yes  | □ No                 |        |                     |  |  |
| Are there antibodies against the selected antigen commercially available?  |                      |        |                     |  |  |
| 3. ANTIBODIES TO BE US   | ED IN                |        |                     |  |  |
| O. AITTIBODIES TO BE 03  |                      |        |                     |  |  |
| Western Blot   | ☐ Yes                | □ No   | ☐ I am not sure yet |  |  |
| ELISA  | ☐ Yes                | □ No   | ☐ I am not sure yet |  |  |
| Immunhistochemistry  | ☐ Yes                | □ No   | ☐ I am not sure yet |  |  |
| Immunofluorescence assay (IFA)   | ☐ Yes                | □ No   | ☐ I am not sure yet |  |  |
|  |                      |        |                     |  |  |
| Immunoassay<br>development   | ☐ Yes                | □ No   | ☐ I am not sure yet |  |  |

Questionnaire - Monoclonal antibody development against an antibody

FB-556, V02



# QUESTIONNAIRE – MONOCLONAL ANTIBODY DEVELOPMENT AGAINST AN ANTIBODY

## 4. PREPARATION OF CELL CULTURE SUPERNATANT FOR TESTING Should preservatives be added prior to cell culture supernatant shipment? ☐ Yes, please add the following: П No ☐ NaN<sub>3</sub> ☐ ProClin □ 0.2 µm filtrated ☐ Not filtrated ☐ Other, please specify: 5. DO YOU REQUIRE FURTHER MAB-RELATED SERVICES FROM BIOGENES **Modification:** ☐ Yes □ No If yes, please specify: **Production:** ☐ Yes □ No Pair search (Capture/Detector): ☐ Yes □ No Immunoassay development: ☐ Yes □ No If yes, please specify: Storage of cryo cultures at BioGenes: ☐ Yes □ No ☐ Without taking care



# QUESTIONNAIRE – MONOCLONAL ANTIBODY DEVELOPMENT AGAINST AN ANTIBODY

### 6. PLEASE PROVIDE ADDITIONAL INFORMATION ON:

| Planned timelines  |       |
|--|-------|
|  |       |
| Payment planned directly or via a purchasing platform (e.g. Scientist. | com)  |
| How did you find out about BioGen                                      | es?   |
| Other information not previously co                                    | vered |
|  |       |
|  |       |
|  |       |
| CLIENT INFORMATION   |       |
| Company/Institution name:  |       |
| Contact person:  |       |
| Address:   |       |
| •  |       |
| •  |       |
| Phone:   |       |
| Email:   |       |
| •  |       |
| Date:  |       |
|  |       |